Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed ...

Indoco Remedies receives US FDA final approval for its ANDA for lacosamide oral solution USP, 10 mg/mL: Our Bureau, Mumbai Friday, January 30, 2026, 14:30 Hrs [IST] Indoco Remedie ...

Wegovy tablets offer a daily oral alternative to injections for weight reduction and reducing cardiovascular risk in eligible adult patients.

EXCLUSIVE — The Environmental Protection Agency has begun a multiyear study to determine the maximum safe level of fluoride in the nation’s drinking water, advancing a key objective of the “Make ...

Lacosamide Oral Solution is used in the treatment of partial onset seizures and primary generalised tonic-clonic seizures in adults and children aged four years and above with epilepsy.

Jan 28 (Reuters) - The U.S. Environmental Protection Agency has released its plan to determine safe levels of fluoride in ...

Shares in Eli Lilly were tracking down this morning after the company revealed data on its oral weight-loss candidate, orforglipron, that seems to have once again disappointed investors. The results ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

Investigator sought to determine whether nelfinavir mesylate plus chemoradiation and image-guided brachytherapy could improve disease-free survival for patients with stage III cervical cancer.

Shortly after reporting weaker-than-expected sales of its injectable GLP-1 drugs, Novo Nordisk revealed clinical results with an oral alternative that suggest it can offer comparable efficacy with ...

Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...

A new drug application (NDA) has been submitted to the FDA seeking approval of lirafugratinib (RLY-4008), a selective FGFR2 ...